Microbiome as a Target for Cancer Therapy.
dysbiosis
estrobolome
fecal microbiota transplantation
probiotics
short chain fatty acids
Journal
Integrative cancer therapies
ISSN: 1552-695X
Titre abrégé: Integr Cancer Ther
Pays: United States
ID NLM: 101128834
Informations de publication
Date de publication:
Historique:
entrez:
23
6
2020
pubmed:
23
6
2020
medline:
31
7
2021
Statut:
ppublish
Résumé
Recently, the microbiome has been gaining traction as a major player regulating various functions that correlate with many pathological conditions, including cancer. The central gut microbiota population has the capability to regulate normal inflammatory, immune, and metabolic functions, and disturbance in the balance of the normal microbiota population can subsequently induce pathological responses that closely relate with the mechanistic development and progression of cancer in various forms and sites. As a disease with major socioeconomic burden partly due to its current therapeutic options, modulating the imbalanced gut microbiota represents a novel option not only as an adjuvant therapy to relieve cancer treatment-related symptoms but also to influence cancer progression itself. In this review, we will discuss how the microbiome, specifically the gut microbiota, could affect cancer pathogenesis and what the effect of gut microbiota-targeting treatment options have on the many aspects of cancer pathologies based on the knowledge of recent years.
Identifiants
pubmed: 32564632
doi: 10.1177/1534735420920721
pmc: PMC7307392
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1534735420920721Références
JAMA Oncol. 2019 Oct 24;:
pubmed: 31647500
Chirurgia (Bucur). 2017 Jul-Aug;112(4):457-468
pubmed: 28862123
Nature. 2016 Jul 06;535(7610):75-84
pubmed: 27383982
Immunol Rev. 2013 Mar;252(1):116-32
pubmed: 23405899
BMC Cancer. 2016 Feb 02;16:52
pubmed: 26841926
J Clin Gastroenterol. 2006 Mar;40(3):235-43
pubmed: 16633129
Annu Rev Microbiol. 1977;31:107-33
pubmed: 334036
Front Microbiol. 2019 Jun 25;10:1050
pubmed: 31293523
Cell Host Microbe. 2011 Oct 20;10(4):324-35
pubmed: 22018233
Gut. 2012 Aug;61(8):1124-31
pubmed: 22115825
BMC Microbiol. 2012 Jul 20;12:144
pubmed: 22817758
Nutrients. 2018 Nov 01;10(11):
pubmed: 30388851
Ann N Y Acad Sci. 2011 Jul;1229:147-55
pubmed: 21793850
Int J Cancer. 2019 Oct 15;145(8):2021-2031
pubmed: 30458058
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Cell. 2019 Aug 8;178(4):795-806.e12
pubmed: 31398337
J Natl Cancer Inst. 2016 Apr 22;108(8):
pubmed: 27107051
Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):E1306-15
pubmed: 26884164
J Nutr. 2007 Nov;137(11 Suppl):2493S-2502S
pubmed: 17951492
Cancer Immunol Immunother. 2017 Jun;66(6):787-798
pubmed: 28299466
Oncol Lett. 2019 Mar;17(3):2836-2848
pubmed: 30854059
Aliment Pharmacol Ther. 1998 Jun;12(6):499-507
pubmed: 9678808
Cancer Med. 2019 Jun;8(6):3250-3260
pubmed: 31062522
Oral Dis. 2005 May;11(3):151-6
pubmed: 15888105
Sci Rep. 2017 Aug 23;7(1):9168
pubmed: 28835659
J Transl Med. 2005 Jul 07;3:27
pubmed: 15987522
Curr Opin Gastroenterol. 2014 Jan;30(1):34-9
pubmed: 24241245
Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3880-5
pubmed: 15004274
Medicina (Kaunas). 2019 Mar 29;55(4):
pubmed: 30934960
Front Immunol. 2019 Jul 23;10:1634
pubmed: 31396208
Semin Cancer Biol. 2019 Apr;55:28-36
pubmed: 29782923
Am J Clin Oncol. 2016 Feb;39(1):98-106
pubmed: 26558876
JAMA. 2017 Jul 4;318(1):102
pubmed: 28672320
Nature. 2010 Mar 4;464(7285):59-65
pubmed: 20203603
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Oncoimmunology. 2016 Apr 25;5(6):e1163462
pubmed: 27471638
EBioMedicine. 2019 Jun;44:730-740
pubmed: 30940601
Nat Med. 2016 Oct 06;22(10):1079-1089
pubmed: 27711063
Nature. 2016 Jul 06;535(7610):65-74
pubmed: 27383981
Medicine (Baltimore). 2017 Oct;96(43):e8418
pubmed: 29069041
Nat Immunol. 2011 Nov 20;13(2):144-51
pubmed: 22101730
Lancet. 1983 May 7;1(8332):1034-7
pubmed: 6133071
Front Cell Infect Microbiol. 2019 Apr 18;9:112
pubmed: 31065547
Benef Microbes. 2018 Dec 7;9(6):975-983
pubmed: 30353740
Circ Res. 2017 Mar 31;120(7):1183-1196
pubmed: 28360349
Appl Environ Microbiol. 2000 Apr;66(4):1321-7
pubmed: 10742206
Fed Pract. 2016 Feb;33(Suppl 1):22S-25S
pubmed: 30766201
Cochrane Database Syst Rev. 2018 Aug 31;8:CD008831
pubmed: 30168576
Nutr Rev. 2012 Aug;70 Suppl 1:S38-44
pubmed: 22861806
Microbes Infect. 2003 Oct;5(12):1057-63
pubmed: 14554246
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Int J Oral Sci. 2011 Oct;3(4):209-15
pubmed: 22010579
Curr Opin Support Palliat Care. 2015 Jun;9(2):157-62
pubmed: 25872116
BMC Cancer. 2018 Nov 13;18(1):1111
pubmed: 30424722
Front Microbiol. 2019 Sep 04;10:1947
pubmed: 31551944
Immunity. 2013 Aug 22;39(2):372-85
pubmed: 23973224
Science. 2018 Jan 5;359(6371):91-97
pubmed: 29097494
Cancer J. 2014 May-Jun;20(3):181-9
pubmed: 24855005
Biomed Res Int. 2015;2015:314620
pubmed: 26583099
Science. 2015 Nov 27;350(6264):1079-84
pubmed: 26541610
Oncotarget. 2017 Jul 25;8(30):49574-49591
pubmed: 28484095
Biomed Pharmacother. 2018 Mar;99:883-893
pubmed: 29710488
Front Cell Infect Microbiol. 2019 Jun 12;9:206
pubmed: 31245306
EMBO Rep. 2006 Jul;7(7):688-93
pubmed: 16819463
Nature. 2007 Oct 18;449(7164):819-26
pubmed: 17943118
EBioMedicine. 2019 Oct;48:301-315
pubmed: 31594750
Carcinogenesis. 2014 Feb;35(2):249-55
pubmed: 24302613
Microorganisms. 2019 Jan 13;7(1):
pubmed: 30642137
Sci Rep. 2018 Apr 18;8(1):6219
pubmed: 29670191
J Appl Bacteriol. 1991 Jun;70(6):443-59
pubmed: 1938669
Science. 2005 Jun 10;308(5728):1635-8
pubmed: 15831718
Cell. 2016 Jan 28;164(3):337-40
pubmed: 26824647
J Hematol Oncol. 2018 Mar 27;11(1):47
pubmed: 29580257
World J Gastroenterol. 2010 Jan 14;16(2):167-75
pubmed: 20066735
Blood. 2015 Jul 16;126(3):311-8
pubmed: 26012569
Cell. 2016 May 5;165(4):842-53
pubmed: 27133167
Brain Sci. 2018 Jan 16;8(1):
pubmed: 29337870
BMC Gastroenterol. 2019 Jul 24;19(1):131
pubmed: 31340751
J Neuroinflammation. 2019 May 22;16(1):108
pubmed: 31118068
Clin Nutr. 2014 Oct;33(5):761-7
pubmed: 24200199